Question 1

What are the most cited papers from Theralogix (United States)?

Accepted Answer

The most cited paper from Theralogix (United States) is "Amelioration of Chronic Murine Colitis by Peptide-Mediated Transduction of the IκB Kinase Inhibitor NEMO Binding Domain Peptide" (Shaival H. Davé, Jeremy S. Tilstra, Katsuyoshi Matsuoka et al., 2007), with 82 citations. Next come "NF-κB Inhibition Protects against Tumor-Induced Cardiac Atrophy in Vivo" (69) and "NEMO-Binding Domain Peptide Inhibits Constitutive NF-κB Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma" (57).

Question 2

Which research topics does Theralogix (United States) publish most on?

Accepted Answer

By volume in 2022-now: Global Energy and Sustainability Research, Nutrition, Genetics, and Disease, Geological and Geophysical Studies and Consumer Attitudes and Food Labeling.

Question 3

Which fields of science does Theralogix (United States) work in?

Accepted Answer

In all years, 41% of research at Theralogix (United States) is in Physical Sciences, 34% in Health Sciences. Its largest fields are Engineering (22%), Medicine (22%), Biochemistry, Genetics and Molecular Biology (13%).